Kearns-Sayre Syndrome (KSS) is a subtype of chronic progressive external ophthalmoplegia (CPEO). The 3 main symptoms of KSS are onset before 20 years of age, CPEO, and pigmented retinopathy. At least one of the following symptoms is accompanied: complete heart block, cerebrospinal fluid protein greater than 100 mg/dL, cerebellar ataxia, short stature, deafness, dementia, and endocrine abnormality. Since Kearns and Sayre first reported KSS in 1958, there have been reports of mtDNA deletions at different locations and sizes in many patients. The most common deletion is marked as the “common 4977 bp deletion,” accounting for more than one-third of all cases. The central nervous system (CNS) involvement of the disease is reflected in the degree of MRI abnormalities, including hyperintensity of fluid-attenuated inversion recovery (FLAIR) sequence in the brainstem, globus pallidus, thalamus, and cerebellar and cerebellar white matter. Here, we report a case of a 21-year-old man with KSS who had a novel mutated gene in SLC25A4: NM_001151:c.170G>C in exon 2 and had a special imaging finding of progressive atrophy of unilateral cerebellum.

Case Report. Patient information. The patient is 21-year-old male.

Diagnostic assessment. At the age of 13 years, parents of the patient brought him to a local children's hospital due to a speech rate lower than that of a normal child, with no abnormality found on the children's intelligence.
screening test. Cranial MRI revealed (A1 and C1 in Figure 1) obvious cerebellar vermian sulcus, and mild atrophy was not excluded. His symptom slowly worsened, and significantly worsened at the age of 16 years, specifically with significantly elongated speech, heterogeneous pitch, and often fulminant. He visited a local hospital and cranial MRI revealed (A2, B1 and C2 in Figure 1) revealed slight narrowing of the gyri in the right cerebellar hemisphere and mild atrophy of the right cerebellum, and the above symptoms gradually worsened. At the age of 19, the patient gradually developed right blepharoptosis, the inability to move in the lower and right lower direction (Figure 1), and exhibited double vision, as well as significantly elongated speech, heterogeneous pitch, and often fulminant.

**Clinical findings.** Results of laboratory test, electrophysiological examination, cerebrospinal fluid examination, ECG and other related examinations are provided in the table (Table 2). The OCT showed outer retinal atrophy in the right eye (Figure 2), cranial MRI showed significant atrophy of the right cerebellar hemisphere (A3, B2 and C3 in Figure 1), and cranial contrast-enhanced MRI did not show significant abnormalities. The test result of mitochondrial gene hotspot mutation in MELAS (mitochondrial encephalomyopathy) syndrome using PCR-Sanger was negative (Table 3). The result of copy number variation sequencing (CNV-Seq) using PCR-Sangers sequencing was negative, the test of mitochondrial disease-related nuclear genome using next-generation sequencing (NGS, whole exome sequencing analysis) showed that the patient carried the suspected pathogenic gene of SLC25A4. Then the first-generation sequencing for SLC25A4 gene was performed on his parents, and the results indicated that the NM_001151:c.170G>C heterozygous mutation of SLC25A4 gene occurred in the exon 2 region in both the patient and his mother.

### Table 1 - Patient timeline.

| Dates         | Relevant past medical history and interventions                                                                                                                                                                                                 |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Before 2011   | No relevant past medical history or interventions                                                                                                                                                                                             |
| May, 2011     | Summaries from initial and follow-up visits                                                                                               Diagnostic testing (including dates)                                                                                       |
| August, 2014  | At the age of 16 years, symptoms slowly and significantly worsened, specifically with elongated speech, heterogeneous pitch, and often fulminant. Results revealed obvious sulcus of vermis cerebelli; A2, B1 and C2 are the Cranial MRI images on August 4, 2014 (Figure 1) | Undetermined diagnosis; No clinical intervention                                                                          |
| November, 2017 | At the age of 19 years, the patient gradually developed right blepharoptosis, the inability to move in the lower and right lower direction (Figure 1), and exhibited double vision, as well as significantly elongated speech, heterogeneous pitch, and often fulminant. No diagnostic testing | Undetermined diagnosis; No clinical intervention                                                                          |
| November, 2019 | At the age of 21 years, aggravation of the above symptoms occurred                                                                                                                    | Kearns-Sayre syndrome was diagnosed. The patient received trophic nerve therapy during hospitalization                      |
Figure 1 - MRI images A1 and C1) are the cranial MRI images on May 14, 2011. They reveal obvious sulcus of vermis cerebelli; A2, B1 and C2) are the cranial MRI images on August 4, 2014. They reveal slight narrowing of the gyrus of the right cerebellar hemisphere; A3, B2 and C3) are the cranial MRI images on November 4, 2019. They reveal narrowing of the gyrus of the right cerebellar hemisphere and widening of the sulcus.

Figure 2 - Outer retinal atrophy in the right eye revealed by OCT of both eyes in the Department of Ophthalmology of our hospital in November 2019.
KSS & SLC25A4 mutation … Zhao et al

114 Neurosciences 2022; Vol. 27 (1) www.nsj.org.sa

18.7%), and the patient’s mother had mitochondria DNA depletion (mitochondria/nuclear DNA: 2.7%). This study was approved by the Ethics Committee of the Affiliated Hospital of Chengdu University of TCM.

**Therapeutic intervention.** The patient received trophic nerve therapy during hospitalization.

**Follow-up and outcomes.** The symptoms were not significantly improved. After discharge, the patient continued to be followed up for about half a year by the outpatient department. The above symptoms continued to worsen, without other clinical symptoms.

**Discussion.** The KSS is very rare. Although the exact prevalence of this disease is unknown, a study reported a prevalence of 1.6 cases per 100,000 people in the Finnish population. In this report, the patient had onset at the age of 13, with the clinical manifestations of chronic progressive blepharoptosis (ptosis) and external ophthalmoplegia, diffuse depigmentation of the retinal pigment epithelium, cerebellar ataxia and cerebrospinal fluid protein of 254 mg/dL, and the clinical features were consistent with the diagnosis of KSS.

Genetic screening revealed a novel mutated gene in SLC25A4 in the patient as well as in his mother: NM_001151:c.170G>C in exon 2. Several mutations in SLC25A4 are associated with mitochondrial diseases and are divided into 2 different clinical phenotypes: null recessive mutations leading to mitochondrial myopathy and cardiomyopathy phenotypes, appearing in childhood or early adulthood and characterized by fatigue and exercise intolerance (also known as

**Table 2** - Laboratory examination, electrophysiological examination, cerebrospinal fluid (CSF) examination and other examinations.

| Examinations         | Results   |
|----------------------|-----------|
| Hematology           |           |
| White blood cell     | 5.05*10^9/L |
| Percentage of Neutrophils | 37.5%   |
| Whole blood C-reactive protein | <0.50mg/L |
| Cholesterol          | (-)       |
| Bile acid            | (-)       |
| Liver enzyme         | (-)       |
| Tumor markers        | (-)       |
| Autoimmune antibody profile | (-) |
| Fasting blood glucose| 6.3mmol/l |
| Glycosylated hemoglobin | 5.2     |
| T3                   | 1.61 nmol/L |
| T4                   | 102.5 nmol/L |
| Parathyroid gland hormone | (-) |
| Sex hormone          | (-)       |
| VitB12               | 680 pmol/L |
| Folate               | 11.3 nmol/L |
| Coenzyme Q10         | /         |
| Vitamin E            | (-)       |
| Anti-GAD antibody    | /         |
| Cerebrospinal fluid  |           |
| Total white blood cells | 4.1     |
| Red blood cell       | 10.3      |
| Protein              | 254 mg/dL |
| IgG                  | 1.87 mg/dL |
| EEG                  | (-)       |
| Electromyography     |           |
| F-wave               | (-)       |
| H-reflex             | (-)       |
| Repetitive stim      | (-)       |
| Fundus Optical Tomography (OCT) | Outer retinal atrophy |
| Abdominal ultrasonography | (-) |
| Chest CT             | (-)       |
| ECG                  | Extension of PR interval |

ECG - electrocardiogram, IgG - Immunoglobulin G, EEG - electroencephalogram, T4 - thyroxine

| Test method               | Test Sites | Test results | Reference values |
|---------------------------|------------|--------------|------------------|
| PCR-sanger sequencing     | m.3093     | C            | C                |
|                           | m.3243     | A            | A                |
|                           | m.3244     | G            | G                |
|                           | m.3252     | A            | A                |
|                           | m.3256     | C            | C                |
|                           | m.3258     | T            | T                |
|                           | m.3260     | A            | A                |
|                           | m.3271     | T            | T                |
|                           | m.3291     | T            | T                |
|                           | m.13513    | G            | G                |

**Table 3** - Negative test result of mitochondrial gene hotspot mutation in MELAS (Mitochondrial Encephalomyopathy) syndrome using PCR-Sanger.

**Figure 3** - The physical examination image A) November 1, 2019: both pupils are of the same size and roundness, with a diameter of about 3mm, sensitive to light reflex, blepharoptosis for the right, and mild restriction for movement in the downward and lower right directions; B) April 20, 2020: both pupils are of the same size and roundness, with a diameter of about 3 mm, sensitive to light reflex, blepharoptosis for the right, unable to move in the downward and lower right directions.
KSS & SLC25A4 mutation … Zhao et al

mitochondrial DNA depletion) (type of syndrome 12 [MIM: 615418]) and the condition of pathogenic autosomal dominant progressive external ophthalmoplegia caused by several separate heterozygous mutations in adult (adPEO [MIM: Report 609283]) but the NM_001151:c.170G>C mutation in exon 2 in SLC25A4 has never been reported, and in combination with the clinical manifestations of the patient and his mother, we found that mutations at this site do not necessarily cause the development of KSS, and Sanger sequencing reveals NM_001151.4: c.239G > a (p.a arg80his) heterozygous de novo mutation in SLC25A4. Quantitative polymerase chain reaction revealed that the patient had mitochondrial DNA deletion (mitochondrial/nuclear DNA: 18.7%) (mitochondria DNA depletion (mito-chondria/nuclear DNA: 18.7%)), and the patient’s mother had mitochondria DNA deletion (mitochondria/nuclear DNA: 2.7%). We speculate that KSS can be caused only when the proportion of mutations in the SLC25A4 gene reach a certain degree.

Postmortem neuropathology in KSS patients may sometimes be associated with severe demyelination of white matter tracts in the brain. Central nervous system (CNS) involvement is reflected in the degree of MRI abnormalities, including hyperintensity of fluid-attenuated inversion recovery (FLAIR) sequence in the brainstem, globus pallidus, thalamus, and cerebral and cerebellar white matter. But these findings were not seen in this patient, but rather a significant progressive atrophy of the right cerebellar hemisphere, which has not been reported in previous cases of KSS.

References

1. Tsang SH, Aycinena ARP, Sharma T. Mitochondrial Disorder: Kearns-Sayre Syndrome. Adv Exp Med Biol 2018; 1085: 161-162.
2. Shemesh A, Margolin E. Kearns Sayre Syndrome. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC., 2022.
3. Nguyen MTB, Micieli J, Margolin E. Teaching NeuImages: Kearns-Sayre syndrome. Neurology 2019; 92: e519-e520.
4. Saldaña-Martínez A, Muñoz ML, Pérez-Ramírez G, Montiel-Sosa JF, Montoya J, Emperador S, et al. Whole sequence of the mitochondrial DNA genome of Kearns Sayre Syndrome patients: Identification of deletions and variants. Gene 2019; 688: 171-181.
5. Shimura M, Kuranobu N, Ogawa-Tominaga M, Akiyama N, Sugiyama Y, Ebihara T, et al. Clinical and molecular basis of hepatocerebral mitochondrial DNA depletion syndrome in Japan: evaluation of outcomes after liver transplantation. Orphanet J Rare Dis 2020; 15: 169.
6. Padhy SK, Kumar V, Mandal S. Pigmentary retinopathy in Kearns-Sayre syndrome. BMJ Case Rep 2018; 2018: bcr2018227394.
7. Trivedi M, Goldstein A, Arora G. Prophylactic pacemaker placement at first signs of conduction disease in Kearns-Sayre syndrome. Cardiol Young 2018; 28: 1487-1488.

Case Reports

Case reports will only be considered for unusual topics that add something new to the literature. All Case Reports should include at least one figure. Written informed consent for publication must accompany any photograph in which the subject can be identified. Figures should be submitted with a 300 dpi resolution when submitting electronically. The abstract should be unstructured, and the introductory section should always include the objective and reason why the author is presenting this particular case. References should be up to date, preferably not exceeding 15.